Literature DB >> 8592229

Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme.

H Tsurushima1, S Q Liu, K Tsuboi, Y Yoshii, T Nose, T Ohno.   

Abstract

The authors induced autologous cytotoxic T lymphocytes (CTLs) directly from peripheral blood lymphocytes by preparing a coculture of minced tissue fragments of glioblastoma multiforme (GBM) with interleukins-1, -2, -4, and -6 and interferon-gamma in RHAM alpha medium containing 5% autologous plasma for 2 weeks. At the end of this period, the frequencies of CD3+, CD4+, CD8+, and CD16+ lymphocytes were 95% to 99%, 40% to 62%, 37% to 38%, and 0.2%, respectively. The lymphocytes killed 82% to 100% of the GBM cells within 48 hours at an effector-to-target cell ratio of 1.67, whereas in a separate coculture, autologous lymphokine-activated killer (LAK) cells killed only 33% of GBM cells under the same conditions. The lymphocytes showed no cytotoxicity against LAK-sensitive Daudi cells, natural killer-sensitive K562 cells or autologous fibroblasts grown from the brain tumor, although they did show slight cytotoxicities against allogeneic GBM cell lines. These results lead the authors to suggest that the lymphocyte population contains specific CTLs for autologous brain tumor cells and that these CTLs could be effective in adoptive immunotherapy to combat brain tumor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8592229     DOI: 10.3171/jns.1996.84.2.0258

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  7 in total

1.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

2.  Recycled addition of CD4+ T cell-rich population for induction of human autologous cytotoxic T lymphocytes: A practically efficient method.

Authors:  K Saijo; H Tsurushima; K Tsuboi; T Nose; A Oki; T Ohno
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

3.  Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides.

Authors:  Hideo Tsurushima; Yoshihiko Yoshii; Kam W Leong; Tadao Ohno
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression.

Authors:  A M Donson; N K Foreman
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

5.  Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.

Authors:  H Tsurushima; S Q Liu; K Tuboi; A Matsumura; Y Yoshii; T Nose; K Saijo; T Ohno
Journal:  Jpn J Cancer Res       Date:  1999-05

Review 6.  Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper.

Authors:  Lara Driggers; Jian-Gang Zhang; Elizabeth W Newcomb; Lisheng Ge; Neil Hoa; Martin R Jadus
Journal:  J Neurooncol       Date:  2009-10-04       Impact factor: 4.130

7.  Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18.

Authors:  M Kohyama; K Saijyo; M Hayasida; T Yasugi; M Kurimoto; T Ohno
Journal:  Jpn J Cancer Res       Date:  1998-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.